(2025). Association between Inflammatory Markers and Alzheimer’s Disease among Elderly Patients with Type 2 Diabetes. The Egyptian Journal of Hospital Medicine, 98(1), 20-24. doi: 10.21608/ejhm.2025.401091
. "Association between Inflammatory Markers and Alzheimer’s Disease among Elderly Patients with Type 2 Diabetes". The Egyptian Journal of Hospital Medicine, 98, 1, 2025, 20-24. doi: 10.21608/ejhm.2025.401091
(2025). 'Association between Inflammatory Markers and Alzheimer’s Disease among Elderly Patients with Type 2 Diabetes', The Egyptian Journal of Hospital Medicine, 98(1), pp. 20-24. doi: 10.21608/ejhm.2025.401091
Association between Inflammatory Markers and Alzheimer’s Disease among Elderly Patients with Type 2 Diabetes. The Egyptian Journal of Hospital Medicine, 2025; 98(1): 20-24. doi: 10.21608/ejhm.2025.401091
Association between Inflammatory Markers and Alzheimer’s Disease among Elderly Patients with Type 2 Diabetes
Background: Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM) are prevalent conditions impacting the geriatric demographic. The interplay of inflammation and dysregulated glucose metabolism in T2DM serves as an additional risk factor for the development of AD. Objective: To explore the correlation between inflammatory biomarkers and AD in geriatric patients diagnosed with T2DM. Material and methods: The investigation was conducted on a cohort of 80 participants, stratified into three groups: 30 individuals diagnosed with T2DM, 20 suffering from both T2DM and AD, and 30 healthy controls. Each subject underwent evaluation process that included a detailed review of their medical history, a comprehensive clinical examination, and a cognitive function assessment. Laboratory analyses encompassed the quantification of hs-CRP, serum IL-6, creatinine, postprandial blood glucose (PPS), fasting blood glucose (FBS), HbA1c, and a full lipid profile. Results: Patients with T2DM and concurrent AD demonstrated significantly elevated hs-CRP levels in comparison with those without AD (p < 0.001). Additionally, serum IL-6 concentrations were notably higher in T2DM with AD (mean 22.5 ± 21.5) and T2DM alone (mean 15.5 ± 11.6) in comparison with the control group (mean 6.2 ± 3.2). Subjects with both T2DM and AD also exhibited increased FBS, PPS, and HbA1c in comparison with those with T2DM without AD. Conclusion: Inflammatory biomarkers were elevated in T2DM patients and correlated with an increased risk of AD within this group.
View on SCiNiTO
Top